Evidence map›Paper›PMID 41038159›Full record

ArticleCell reports. Medicine2025

Designer probiotic-based living drugs for uric acid homeostasis control in hyperuricemic mice and rats.

Xianyun Gao, Yiyu Jin, Mengyao Liu, Wenbo Ma, Deqiang Kong, Yang Zhou, Lingxue Niu, Jianli Yin, Haibing Chen, Haifeng Ye and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xianyun GaoShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China.
Yiyu JinShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China.
Mengyao LiuShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China.
Wenbo MaShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China.
Deqiang KongShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China; Shanghai SynBioEra Biotechnology Co., Ltd., Shanghai 200241, China; Shanghai Fengxian District Central Hospital, Shanghai 201499, China.
Yang ZhouShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China; Wuhu Hospital, Health Science Center, East China Normal University, Middle Jiuhua Road 263, Wuhu City, China.
Lingxue NiuShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China.
Jianli YinShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China.
Haibing ChenDepartment of Endocrinology and Metabolism, Shanghai Tenth People's Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai 200072, China. Electronic address: hbchen@tongji.edu.cn.
Haifeng YeShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China; Shanghai SynBioEra Biotechnology Co., Ltd., Shanghai 200241, China. Electronic address: hfye@bio.ecnu.edu.cn.
Ningzi GuanShanghai Frontiers Science Center of Genome Editing and Cell Therapy, Biomedical Synthetic Biology Research Center, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, Shanghai Academy of Natural Sciences (SANS), East China Normal University, Shanghai, China; Shanghai SynBioEra Biotechnology Co., Ltd., Shanghai 200241, China. Electronic address: nzguan@bio.ecnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Engineered probiotics can effectively manage hyperuricemia, a condition characterized by increased serum uric acid (UA) levels, leading to several chronic diseases. In this study, we design a probiotic-based UA level sensing and adjustment (PULSE)-engineered bacterium to maintain UA homeostasis. We generate a UA sensor in the E. coli Nissle 1917 strain based on a UA-responsive transcriptional repressor HucR, integrated with a synthetic promoter. Upon oral administration of engineered probiotics, PULSE cells dynamically regulate urate oxidase expression, reducing UA in the gastrointestinal tract in response to increased serum levels. We have demonstrated the potential of PULSE-engineered bacteria in maintaining UA balance in acute and chronic hyperuricemic mouse and rat models, highlighting the potential for long-term oral administration in reducing hyperuricemia-associated renal damage. Our probiotic-based living drug supports the progress of engineered probiotics as a safe, effective, and patient-friendly alternative to typical therapeutics for chronic disease management.

Indexed as

HomeostasisHyperuricemiaProbioticsUric AcidAnimalsDisease Models, AnimalEscherichia coliMaleMiceMice, Inbred C57BLRatsRats, Sprague-DawleyUrate OxidaseUrate OxidaseUric Aciddesigner cellsengineered probioticshyperuricemic rat modelliving therapeuticsrenal damagesynthetic biologyUA homeostasisurate oxidaseuric acid sensor

Identifiers

PMID41038159
PMCPMC12629798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.